C-YRNHomega-3 epoxyeicosanoid analogs, mitochondrial protection, anti-inflammatory small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
OMEICOS Therapeutics states that atrial fibrillation can be treated and prevented with a novel first-in-class small molecule approach based on natural metabolites of omega-3 fatty acids. The company says these metabolites produce a strong anti-arrhythmic effect and, unlike other anti-arrhythmic drugs, activate an endogenous cardio-protective signaling pathway intended not only to stabilize heart rhythm but also to provide curative effects by preventing electrical and structural remodeling of the heart.
SourceOMEICOS Therapeutics states that its science is driven by understanding and using endogenous signaling pathways, and that its drug candidates are highly potent, stable analogues designed as first-in-class, orally available small molecules with a new mode of action. The company expresses a belief that proprietary knowledge of the body’s own omega-3 fatty acid metabolic processes can be translated into therapeutics for patients with medically underserved diseases, especially cardiovascular conditions such as atrial fibrillation.
SourceOMEICOS Therapeutics states that its scientific approach is based on understanding and using endogenous signalling pathways, especially the body’s own omega-3 fatty acid metabolic processes, to create first-in-class orally available small-molecule drugs. The company presents its candidates as highly potent, stable analogues with a novel mode of action intended to benefit patients with medically underserved diseases, including atrial fibrillation and other areas of high unmet medical need.
SourceOMEICOS Therapeutics states that atrial fibrillation can be treated and prevented with a first-in-class small-molecule approach based on natural metabolites of omega-3 fatty acids. The company says these metabolites produce a strong anti-arrhythmic effect by activating an endogenous cardioprotective signaling pathway that not only stabilizes heart rhythm but may also have curative effects by preventing electrical and structural remodeling of the diseased heart.
SourceOMEICOS Therapeutics states that omega-3 fatty acid metabolites can be turned into broadly deployable therapeutics for inflammatory, cardiovascular, ophthalmology, and other diseases, and that its proprietary approach can improve on natural metabolites by creating first-in-class synthetic analogs with much higher biological activity and better pharmacokinetic properties.
Source